Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003302 · ClinicalTrials.gov registry record · NA
MRI to Detect Breast Tumors in Women
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 1,500
- Enrollment target
NCT00003302 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1,500 participants.
The verdict
NCT00003302, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,500 participants
- Enrollment target
Study Summary
RATIONALE: New imaging procedures, such as MRI, may improve the ability to detect breast tumors. PURPOSE: Diagnostic study to determine the value of MRI in detecting breast tumors in women who have had suspicious mammographic or clinical examinations.
Interventions
- PROCEDURE biopsy
- DIAGNOSTIC_TEST magnetic resonance imaging
- DIAGNOSTIC_TEST mammography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 1998-05 |
| Est. Completion | 2000-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003302
The ClinicalTrials.gov registry entry for NCT00003302 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which biopsy is the first listed.
NCT00003302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003302 about?
NCT00003302 is a clinical study titled "MRI to Detect Breast Tumors in Women". RATIONALE: New imaging procedures, such as MRI, may improve the ability to detect breast tumors. PURPOSE: Diagnostic study to determine the value of MRI in detecting breast tumors in women who have had suspicious mammographic or clinical examinations.
What is the current status of trial NCT00003302?
This trial is currently completed. It is a NA study. The enrollment target is 1,500 participants. The study started on 1998-05. Estimated completion is 2000-06-30.
What interventions are being tested in trial NCT00003302?
The interventions under investigation include: biopsy (PROCEDURE), magnetic resonance imaging (DIAGNOSTIC_TEST), mammography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT00003302?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.